A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

计划入组 515 人 · 首次发布于 2019 年 4 月 30 日

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

计划入组 99 人 · 首次发布于 2011 年 9 月 5 日

First-in-Human Study of KO-947 in Non-Hematological Malignancies

计划入组 61 人 · 首次发布于 2017 年 2 月 13 日

MK-7246

ORI-7246

KO-2806

SHENYAN SANSHAIN FARMASYUTIKAL KO., LTD., PREDSTAVITELSTVO

Russia

Kura Oncology

United States

UNIVERSITY OF SOUTH AUSTRALIA

Australia

Kura Oncology spins out Caspian Therapeutics with $50M to develop menin inhibitors for diabetes

Kura Oncology's KO-2806 Shows Promise in Combination Therapy for Renal Cell Carcinoma

Kura Oncology Showcases Preclinical Data for Next-Generation FTI KO-2806 in Combination Therapies